CapsoVision's Losses Widen Despite Revenue Growth Post-IPO

TL;DR

**CapsoVision's IPO cash infusion is quickly being burned through by R&D, making it a speculative bet on future product success, not current profitability.**

AI Summary

CapsoVision, Inc. (CV) reported a net loss of $7.921 million for the three months ended September 30, 2025, an increase from $5.794 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $17.921 million, up from $15.259 million in 2024. Revenue saw growth, reaching $3.538 million for the quarter, up from $2.966 million year-over-year, and $9.636 million for the nine months, compared to $8.304 million in 2024. Operating expenses significantly increased to $9.933 million for the quarter, primarily driven by a substantial rise in research and development to $6.090 million and general and administrative expenses to $2.070 million. The company completed its Initial Public Offering (IPO) on July 3, 2025, raising approximately $23.37 million in net proceeds, which significantly boosted its cash and cash equivalents to $17.787 million as of September 30, 2025, from $9.319 million at December 31, 2024. Despite the IPO, the company continues to incur operating losses and negative cash flows, with $15.178 million used in operating activities for the nine months ended September 30, 2025, indicating ongoing reliance on financing to sustain operations and product development, particularly for CapsoColon 3D.

Why It Matters

CapsoVision's continued significant operating losses and negative cash flow, even after a $23.37 million IPO, signal a high-risk investment. While revenue is growing, the substantial increase in R&D and G&A expenses, particularly for the in-development CapsoColon 3D, suggests a long path to profitability. Investors need to weigh the potential of their GI imaging technology against the company's burn rate and the competitive landscape, which includes established medical device players. Employees face ongoing pressure to deliver on product development milestones, and customers await the commercialization of new technologies like CapsoColon 3D, which could disrupt the colonoscopy market if successful.

Risk Assessment

Risk Level: high — CapsoVision has incurred operating losses and negative cash flows from inception, with a net loss of $17.921 million and $15.178 million in cash used in operating activities for the nine months ended September 30, 2025. The company explicitly states it expects to continue similar circumstances until sales yield further growth and break-even, indicating a significant going concern risk despite the recent IPO proceeds.

Analyst Insight

Investors should approach CapsoVision with extreme caution, recognizing it as a high-risk, high-reward play. Monitor the progress of CapsoColon 3D's FDA clearance and subsequent commercialization closely, as this is the primary driver for future revenue growth and potential profitability. Consider a small, speculative position only if you have a high tolerance for risk and a long-term investment horizon.

Financial Highlights

debt To Equity

0.25

revenue

$9,636,000

operating Margin

-187.6%

total Assets

$25,661,000

total Debt

$5,219,000

net Income

-$17,921,000

eps

N/A

gross Margin

54.2%

cash Position

$17,787,000

revenue Growth

+16.0%

Revenue Breakdown

Key Numbers

• $17.921M — Net Loss (for the nine months ended September 30, 2025, increased from $15.259M in 2024)
• $9.636M — Net Revenue (for the nine months ended September 30, 2025, up from $8.304M in 2024)
• $15.178M — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025, indicating significant cash burn)
• $23.37M — Net Proceeds from IPO (received on July 3, 2025, boosting cash reserves)
• $17.787M — Cash and Cash Equivalents (as of September 30, 2025, up from $9.319M at December 31, 2024)
• $12.589M — Research and Development Expenses (for the nine months ended September 30, 2025, increased from $12.004M in 2024)
• $5.101M — General and Administrative Expenses (for the nine months ended September 30, 2025, increased from $2.754M in 2024)
• 46,843,225 — Common Stock Shares Outstanding (as of November 11, 2025, significantly increased post-IPO)

Key Players & Entities

• CapsoVision, Inc. (company) — registrant of the 10-Q filing
• FDA (regulator) — approves medical devices like CapsoCam Plus and CapsoColon 3D
• CapsoCam Plus (company) — on-market small intestine imaging device
• CapsoColon 3D (company) — in-development large intestine imaging device
• Nasdaq Stock Market LLC (company) — exchange where CV common stock is registered
• Taiwan, Republic of China (company) — location of CapsoVision's branch office and suppliers
• Private Securities Litigation Reform Act of 1995 (regulator) — governs forward-looking statements
• Jumpstart Our Business Startups Act of 2012 (regulator) — JOBS Act, relevant for emerging growth companies

FAQ

Risk Factors

• Continued Operating Losses and Cash Burn [high — financial]: CapsoVision reported a net loss of $17.921 million for the nine months ended September 30, 2025, an increase from $15.259 million in the prior year. The company used $15.178 million in operating activities during the same period, indicating a significant cash burn. This necessitates ongoing reliance on financing to sustain operations and product development.
• High R&D Investment for Product Development [medium — operational]: Research and development expenses increased to $12.589 million for the nine months ended September 30, 2025, up from $12.004 million in 2024. This substantial investment is crucial for the development of products like CapsoColon 3D, but it contributes significantly to the company's operating losses.
• Post-IPO Cash Burn Despite Raised Capital [high — financial]: Although the company raised $23.37 million in net proceeds from its IPO on July 3, 2025, boosting cash to $17.787 million, it continues to incur operating losses and negative cash flows. The substantial increase in operating expenses, particularly R&D and G&A, outpaces revenue growth.
• Increased General and Administrative Expenses [medium — operational]: General and administrative expenses rose to $5.101 million for the nine months ended September 30, 2025, from $2.754 million in 2024. This significant increase, alongside R&D, contributes to the widening operating loss.
• Regulatory Compliance for Medical Devices [high — regulatory]: As a medical device company, CapsoVision is subject to stringent regulatory oversight from bodies like the FDA. Any delays or failures in obtaining or maintaining regulatory approvals for its products, such as CapsoColon 3D, could materially impact its ability to generate revenue and achieve profitability.

Industry Context

The medical device industry, particularly in areas like gastrointestinal diagnostics, is characterized by significant R&D investment, long product development cycles, and stringent regulatory hurdles. Companies like CapsoVision compete on technological innovation, clinical efficacy, and market adoption, often requiring substantial capital to fund growth and navigate regulatory pathways.

Regulatory Implications

CapsoVision operates in a highly regulated environment. Compliance with FDA and other global health authorities is paramount for product approval and market access. Any adverse regulatory actions or delays in approvals for its innovative technologies could severely impact its financial performance and future prospects.

What Investors Should Do

1. Monitor R&D spend and its conversion to revenue.
2. Analyze the burn rate and cash runway post-IPO.
3. Evaluate the growth trajectory of revenue against operating expenses.
4. Assess the competitive landscape and market adoption of CapsoColon 3D.

Key Dates

• 2025-07-03: Initial Public Offering (IPO) — The company raised approximately $23.37 million in net proceeds, significantly bolstering its cash position and providing capital for future operations and development.
• 2025-09-30: End of Q3 2025 — Reported net loss of $7.921 million for the quarter and $17.921 million for the nine months, with revenue of $3.538 million for the quarter and $9.636 million for the nine months. Cash and cash equivalents stood at $17.787 million.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents were $9.319 million. This serves as a baseline for the significant cash increase post-IPO.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents a negative balance in retained earnings. (CapsoVision has an accumulated deficit of $148.271 million as of September 30, 2025, highlighting its history of unprofitability.)

Convertible Preferred Stock

A class of preferred stock that can be converted into a specified number of common stock shares. (The company had a liquidation preference of $152.378 million associated with its convertible preferred stock as of December 31, 2024, which is no longer listed as a separate line item as of September 30, 2025, likely due to conversion or redemption post-IPO.)

Operating lease right-of-use assets

An asset recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (CapsoVision has $935 million in these assets as of September 30, 2025, indicating ongoing lease commitments for its operations.)

Stockholders' Equity (Deficit)

The net worth of a company, calculated as total assets minus total liabilities. A deficit means liabilities exceed assets. (CapsoVision shows a deficit in stockholders' equity of $129.510 million at December 31, 2024, which improved to a positive $20.442 million by September 30, 2025, largely due to the IPO proceeds.)

Year-Over-Year Comparison

CapsoVision's financial performance shows a mixed picture compared to the prior year. Revenue for the nine months ended September 30, 2025, increased by 16.0% to $9.636 million from $8.304 million in 2024. However, the net loss widened significantly to $17.921 million from $15.259 million, driven by a substantial increase in operating expenses, particularly R&D and G&A. The company's cash position dramatically improved due to its IPO, but the operating cash burn remains a concern.

Key Financial Figures

• $0.001 — ange on which registered common stock, $0.001 par value per share CV The Nasdaq Stock

Filing Documents

• cv-20250930.htm (10-Q) — 1420KB
• cv-20251113xex1001.htm (EX-10.01) — 68KB
• cv-20251113xex1002.htm (EX-10.02) — 62KB
• cv-20251113xex1003.htm (EX-10.03) — 67KB
• cv-20251113xex1004.htm (EX-10.04) — 68KB
• cv-20251113xex1005.htm (EX-10.05) — 16KB
• cv-20251113xex1006.htm (EX-10.06) — 15KB
• cv-20251113xex1007.htm (EX-10.07) — 54KB
• cv-20251113xex1008.htm (EX-10.08) — 72KB
• cv-20251113xex311.htm (EX-31.1) — 9KB
• cv-20251113xex312.htm (EX-31.2) — 9KB
• cv-20251113xex321.htm (EX-32.1) — 5KB
• cv-20251113xex322.htm (EX-32.2) — 5KB
• image.jpg (GRAPHIC) — 34KB
• 0001378325-25-000040.txt ( ) — 7675KB
• cv-20250930.xsd (EX-101.SCH) — 39KB
• cv-20250930_cal.xml (EX-101.CAL) — 57KB
• cv-20250930_def.xml (EX-101.DEF) — 219KB
• cv-20250930_lab.xml (EX-101.LAB) — 592KB
• cv-20250930_pre.xml (EX-101.PRE) — 466KB
• cv-20250930_htm.xml (XML) — 850KB

- Financial Information

Part I - Financial Information 1

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 1 Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 3 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 4 Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 6 Notes to Condensed Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 33

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 46

Controls and Procedures

Item 4. Controls and Procedures 46

- Other Information

Part II - Other Information 48

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 48

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 93

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 93

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 93

Other Information

Item 5. Other Information 93

Exhibits

Item 6. Exhibits 94

Signatures

Signatures 95 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this Quarterly Report on Form 10-Q constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this Quarterly Report on Form 10-Q may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this Quarterly Report on Form 10-Q might not occur. While we believe we have identified material risks, these risks and uncertainties are not exhaustive. The outcome of the events described in these forward-looking statements is subject to

Forward-looking statements include, but are not limited to, statements about

Forward-looking statements include, but are not limited to, statements about: our expectations regarding the acceptance of our products by patients and doctors; our expectations regarding the potential market size for our current CapsoCam Plus capsule and CapsoCam Colon (once FDA cleared) and those markets that we may pursue; our plans to increase small bowel capsule sales following recent 510(k) clearance for pediatric use and telehealth supervision and related products currently under development; our expected receipt of and related timing for FDA 510(k) clearance of our CapsoCam Colon and related sales; our plans and efforts to expand into new indications in terms of new GI pathologies and expanded patient populations; our plans and efforts to introduce enhancements and improvements to our products and technologies, including the AI capabilities incorporated into our products; our commercialization capabilities and strategies, including our plans to increase revenues and sales capabilities in and outside the United States (the "U.S."); the implementation of our strategic plan for our business and products and technology; our relationships with, and capabilities of, our assembly manufacturers and component suppliers; the protection of our intellectual property (including our AI capabilities) including through patents and trade secret protections; the expected performance of our products; our ability to manage our growth; ii the anticipated use of proceeds from this offering; our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") or smaller reporting company under U.S. securities laws; estimates of our expenses, future revenue, capital requirements, our needs for additional financing, and our ability to obtain additional capital; our ability to continue as a going concern; and our future financial performance. We caution you not to place undue

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CAPSOVISION, INC. CONDENSED BALANCE SHEETS (UNAUDITED) (in thousands, except par value and share amounts) September 30, 2025 December 31, 2024 ASSETS Current Assets Cash and cash equivalents $ 17,787 $ 9,319 Accounts receivable, net 1,870 2,001 Inventory 3,187 2,629 Prepaid expenses and other current assets 1,201 898 Total current assets 24,045 14,847 Property and equipment, net 640 720 Operating lease right-of-use assets 935 1,195 Other long-term assets 41 41 TOTAL ASSETS $ 25,661 $ 16,803 LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable $ 1,345 $ 749 Accrued expenses and other current liabilities 2,790 569 Deferred revenue 106 132 Operating lease liabilities – current 394 351 Total current liabilities 4,635 1,801 Operating lease liabilities – long-term 584 887 Total liabilities 5,219 2,688 Commitments and contingencies - Note 9 Convertible Preferred Stock (each Series: $0.001 par value) Series A, B, C, C-1, D, D-1, D-2, E, F-1, F-2, G, G-1, H: none and 153,682,280 shares authorized, none and 38,665,583 issued and outstanding, and liquidation preference of none and $ 152,378 as of September 30, 2025 and December 31, 2024, respectively — 143,625 The accompanying notes are an integral part of these condensed financial statements. 1 CAPSOVISION, INC. CONDENSED BALANCE SHEETS (UNAUDITED) (continued) (in thousands, except par value and share amounts) September 30, 2025 December 31, 2024 Convertible Preferred Stock (each Series: $0.001 par value) (continued) Total convertible preferred stock — 143,625 Stockholders' Equity Common stock, $ 0.001 par value: 300,000,000 and 190,000,000 shares authorized; 46,798,901 and 2,090,945 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 47 2 Additional paid-in capital 168,666 838 Accumulated deficit ( 148,271 ) ( 130,350 ) Total stockholders' equity (defici

View Full Filing

View this 10-Q filing on SEC EDGAR